ATE215966T1 - Interleukin-1-inhibitoren - Google Patents

Interleukin-1-inhibitoren

Info

Publication number
ATE215966T1
ATE215966T1 AT92114773T AT92114773T ATE215966T1 AT E215966 T1 ATE215966 T1 AT E215966T1 AT 92114773 T AT92114773 T AT 92114773T AT 92114773 T AT92114773 T AT 92114773T AT E215966 T1 ATE215966 T1 AT E215966T1
Authority
AT
Austria
Prior art keywords
interleukin
inhibitor
inhibitors
recombinant
beta
Prior art date
Application number
AT92114773T
Other languages
English (en)
Inventor
Charles H Hannum
Stephan P Eisenberg
Robert C Thompson
William P Arend
Fenneke G Joslin
Andreas Sommer
Original Assignee
Amgen Inc
Univ Colorado Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Univ Colorado Foundation filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE215966T1 publication Critical patent/ATE215966T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/30Fuel from waste, e.g. synthetic alcohol or diesel
AT92114773T 1988-05-27 1989-05-26 Interleukin-1-inhibitoren ATE215966T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19991588A 1988-05-27 1988-05-27
US23871388A 1988-08-31 1988-08-31
US24852188A 1988-09-23 1988-09-23
US26653188A 1988-11-03 1988-11-03

Publications (1)

Publication Number Publication Date
ATE215966T1 true ATE215966T1 (de) 2002-04-15

Family

ID=27498356

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92114773T ATE215966T1 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren
AT89109540T ATE88502T1 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT89109540T ATE88502T1 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren.

Country Status (14)

Country Link
EP (3) EP0541920B1 (de)
KR (1) KR0148009B1 (de)
AT (2) ATE215966T1 (de)
CA (1) CA1341322C (de)
DE (4) DE68906077T2 (de)
ES (2) ES2018750T3 (de)
GR (1) GR900300115T1 (de)
HK (2) HK1017821A1 (de)
IE (1) IE66712B1 (de)
IL (1) IL90423A (de)
LU (1) LU90943I2 (de)
NL (1) NL300091I2 (de)
NZ (1) NZ229326A (de)
SG (1) SG59969A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1991008285A1 (en) * 1989-11-29 1991-06-13 Synergen, Inc. Production of recombinant human interleukin-1 inhibitor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU7683391A (en) * 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
WO1991017249A1 (en) * 1990-05-01 1991-11-14 Cetus Corporation Interleukin-1 antagonist and uses thereof
CA2118119C (en) * 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
HUP9900169A2 (hu) * 1995-09-13 2000-03-28 Takeda Chemical Industries, Ltd. Immunoszuppresszáns hatású kinolin- vagy kinozalinszármazékok és ezeket tartalmazó gyógyászati készítmények
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
US7205381B2 (en) 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
CA2326066A1 (en) 1998-04-03 1999-10-14 Hyseq, Inc. A interleukin-1 receptor antagonist and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
AU6296899A (en) * 1998-10-08 2000-04-26 Zymogenetics Inc. Interleukin-1 homolog
CA2393661A1 (en) * 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
BR112013003646B1 (pt) 2010-07-29 2021-09-08 Eleven Biotherapeutics, Inc. Proteína isolada que compreende um domínio de citocina da família de interleucina-1 (il-1) quimérica, seu método de preparação, composição farmacêutica e usos, bem como, ácido nucleico, vetor, e célula hospedeira
WO2012076194A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit cytokin-antagonist und corticosteroid
WO2012076193A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
ES2884813T3 (es) 2013-03-13 2021-12-13 Buzzard Pharmaceuticals AB Formulaciones de citoquina quimérica para administración ocular
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0138919B1 (ko) * 1987-08-26 1998-04-30 프레드릭 에이. 유스티스, 3세 인터루킨-1 저해제를 암호하는 재조합 dna 분자를 제조하는 방법

Also Published As

Publication number Publication date
ES2018750T3 (es) 1994-10-16
NL300091I2 (nl) 2002-08-01
ES2018750A4 (es) 1991-05-16
EP0541920B1 (de) 2002-04-10
NL300091I1 (nl) 2002-07-01
DE68906077D1 (de) 1993-05-27
EP0343684A1 (de) 1989-11-29
CA1341322C (en) 2001-11-27
ATE88502T1 (de) 1993-05-15
SG59969A1 (en) 1999-02-22
DE10299011I1 (de) 2002-07-18
IE891781L (en) 1989-11-27
DE68929387T2 (de) 2002-08-14
IL90423A0 (en) 1990-01-18
ES2176181T3 (es) 2002-12-01
IE66712B1 (en) 1996-01-24
DE343684T1 (de) 1990-11-08
EP1133995A3 (de) 2001-09-26
KR0148009B1 (ko) 1998-08-01
IL90423A (en) 2000-07-26
KR900700618A (ko) 1990-08-16
EP0541920A1 (de) 1993-05-19
IE950317L (en) 1989-11-27
DE68929387D1 (de) 2002-05-16
EP0343684B1 (de) 1993-04-21
NZ229326A (en) 1992-12-23
DE68906077T2 (de) 1993-07-29
LU90943I2 (fr) 2002-09-30
GR900300115T1 (en) 1991-09-27
HK1017821A1 (en) 1999-11-26
HK1039901A1 (zh) 2002-05-17
DE10299011I2 (de) 2006-03-16
EP1133995A2 (de) 2001-09-19

Similar Documents

Publication Publication Date Title
DE68906077D1 (de) Interleukin-1-inhibitoren.
IT8721618A0 (it) Prodecimento per la depurazione bilogica di acque reflue.
IT8620860A0 (it) Procedimento per l'esercizio di un estrusore.
DE69030582D1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
IT8521037A0 (it) Procedimento per la polimerizzazione di isoprene.
IT1198897B (it) Struemento chirurgico per la asportazione di piccole varici
IT1230333B (it) Procedimento per la fabbricazione di pezzi stampati ceramici.
IT8721560A0 (it) Procedimento per la purificazione di interferone.
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
IT8520090A0 (it) Procedimento di purificazione di un enzima.
IT8722452A0 (it) Processo per la sintesi di una n ndialchil idrossilammina.
ES510546A0 (es) "procedimiento de preparar derivados de n-(n-metil-rn(n-aminosulfenil disubstituido)carbamoil)oxi)tioacetamidato de s-metilo".
DE209855T1 (de) Aminosaeure-derivate, nuetzlich zur deaktivation von enzymen.
DE3674575D1 (de) Verwendung von optisch-aktiven carboalkylierten aminoalkohole zur trennung von optischen isomeren.
IT8620828A0 (it) Procedimento per la produzione di una l-aspartil-l-fenilalanina n-protetta.
RU2004196C1 (ru) Способ резекции желудка в эксперименте
IT8819389A0 (it) Procedimento per depurazione di acque di scarico industriale.
IT8821083A0 (it) Procedimento per la realizzazione di fogli autoadesivi.
IT8820665A0 (it) Procedimento per la preparazione di (s) e (r) alfa, beta isopropilidenglicerolo.
ITRM940151A0 (it) Impiego di esteruretani per la riconcia.
IT8720114A0 (it) Procedimento migliorato per la purificazione di l-carnitinato di l-carnitina.
ITTO910025A0 (it) Procedimento ed impianto per la depurazione di fanghi biologici
CS719388A1 (en) Derivatives of thioallophanic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time